Search Results - "Rofelty, Angela"

Modulation of ERK and breast cancer cell growth by estrogen receptors (613.3) by Rofelty, Angela, Schmitt, John

“…Estrogen Receptors participate in both genomic and non‐genomic signaling pathways that affect breast cancer cell growth and proliferation. The growth‐enhancing…”
Get full text

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells by Edwards, David K., Watanabe-Smith, Kevin, Rofelty, Angela, Damnernsawad, Alisa, Laderas, Ted, Lamble, Adam, Lind, Evan F., Kaempf, Andy, Mori, Motomi, Rosenberg, Mara, d'Almeida, Amanda, Long, Nicola, Agarwal, Anupriya, Sweeney, David Tyler, Loriaux, Marc, McWeeney, Shannon K., Tyner, Jeffrey W.

“…To identify new therapeutic targets in acute myeloid leukemia (AML), we performed small-molecule and small-interfering RNA (siRNA) screens of primary AML…”
Get full text

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoidderived hematologic malignancies by Kurtz, Stephen E., Eide, Christopher A., Kaempf, Andy, Khanna, Vishesh, Savage, Samantha L., Rofelty, Angela, English, Isabel, Ho, Hibery, Pandya, Ravi, Bolosky, William J., Poon, Hoifung, Deininger, Michael W., Collins, Robert, Swords, Ronan T., Watts, Justin, Pollyea, Daniel A., Medeiros, Bruno C., Traer, Elie, Tognon, Cristina E., Mori, Motomi, Druker, Brian J., Tyner, Jeffrey W.

“…Translating the genetic and epigenetic heterogeneity underlying human cancers into therapeutic strategies is an ongoing challenge. Large-scale sequencing…”
Get full text

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies by Kurtz, Stephen E, Eide, Christopher A, Kaempf, Andy, Khanna, Vishesh, Savage, Samantha L, Rofelty, Angela, English, Isabel, Ho, Hibery, Pandya, Ravi, Bolosky, William J, Poon, Hoifung, Deininger, Michael W, Collins, Robert, Swords, Ronan T, Watts, Justin, Pollyea, Daniel A, Medeiros, Bruno C, Traer, Elie, Tognon, Cristina E, Mori, Motomi, Druker, Brian J, Tyner, Jeffrey W

“…Translating the genetic and epigenetic heterogeneity underlying human cancers into therapeutic strategies is an ongoing challenge. Large-scale sequencing…”
Get full text

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis by Zhang, Haijiao, Wilmot, Beth, Bottomly, Daniel, Dao, Kim-Hien T., Stevens, Emily, Eide, Christopher A., Khanna, Vishesh, Rofelty, Angela, Savage, Samantha, Reister Schultz, Anna, Long, Nicola, White, Libbey, Carlos, Amy, Henson, Rachel, Lin, Chenwei, Searles, Robert, Collins, Robert H., DeAngelo, Daniel J., Deininger, Michael W., Dunn, Tamara, Hein, Than, Luskin, Marlise R., Medeiros, Bruno C., Oh, Stephen T., Pollyea, Daniel A., Steensma, David P., Stone, Richard M., Druker, Brian J., McWeeney, Shannon K., Maxson, Julia E., Gotlib, Jason R., Tyner, Jeffrey W.

“…Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), and myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) are…”
Get full text

Estrogen Receptor Alpha Utilizes TRP Channel 6 in Cancer Cell Growth by Rawlings, Emily J, Rofelty, Angela J, Schmitt, John M

“…Abstract only The rapid signaling effects of the hormone estrogen (E2) are mediated through estrogen receptor alpha (ERα) that activates a Ca 2+ /calmodulin…”
Get full text

Estrogen Receptor α Regulates ERK in MCF‐7 Cells by Rofelty, Angela J., Schmitt, John M.

“…Abstract only Estrogen (E2) signaling significantly affects breast tumorigenesis by enhancing cell growth and preventing apoptosis. The actions of estrogen in…”
Get full text

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples by Edwards V, David K, Sweeney, David Tyler, Ho, Hibery, Eide, Christopher A, Rofelty, Angela, Agarwal, Anupriya, Liu, Selina Qiuying, Danilov, Alexey V, Lee, Patrice, Chantry, David, McWeeney, Shannon K, Druker, Brian J, Tyner, Jeffrey W, Spurgeon, Stephen E, Loriaux, Marc M

“…In many malignancies, the tumor microenvironment includes CSF1R-expressing supportive monocyte/macrophages that promote tumor cell survival. For chronic…”
Get full text

Abstract 1087: CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD by Edwards, David K., Javidi-Sharifi, Nathalie, Rofelty, Angela, Gordon, Max, Roth-Carter, Riley, Tardi, Paul, Mayer, Lawrence, Tyner, Jeffrey W.

“…Introduction: CPX-351 (Vyxeos) is a liposomal combination of cytarabine and daunorubicin at a synergistic 5:1 molar ratio. Recently, CPX-351 has been shown to…”
Get full text

Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation by Edwards, David K., Javidi-Sharifi, Nathalie, Rofelty, Angela, Rosenfeld, Claire, Roth-Carter, Riley, Tardi, Paul, Mayer, Lawrence, Tyner, Jeffrey W.

“…Introduction: CPX-351 (Vyxeos), a liposomal combination of cytarabine and daunorubicin co-encapsulated at a synergistic 5:1 molar ratio, has recently been…”
Get full text

Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations by Zhang, H, Reister Schultz, A, Luty, S, Rofelty, A, Su, Y, Means, S, Bottomly, D, Wilmot, B, McWeeney, S K, Tyner, J W

“…An increasing number of variants of unknown significance are being identified in leukemia patients with the application of deep sequencing and these include…”
Get full text

Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations by Eide, Christopher A., Kurtz, Stephen E, Kaempf, Andy, Park, Andrew, Rofelty, Angela, Wilmot, Beth, Bottomly, Daniel, McWeeney, Shannon K., Tognon, Cristina E., Mori, Motomi, Tyner, Jeffrey W., Druker, Brian J.

“…Background: One of the daunting challenges for the use of targeted therapies in the treatment of acute myeloid leukemia (AML) has been the marked heterogeneity…”
Get full text

Abstract 2452: Detailed genomic characterization of CNL/aCML/MPN-U/CMML reveals disease subgroups that may benefit from rationally-designed combination therapies by Zhang, Haijiao, Wilmot, Beth, Bottomly, Daniel, White, Libbey, Segerdell, Erik, McWeeney, Shannon K., Khanna, Vishesh, Rofelty, Angela, Means, Sophie, Junio, Brian, Savage, Samantha, Stevens, Emily, Dao, Kim-Hien, Maxson, Julia E., Tyner, Jeffrey W.

“…Purpose: Chronic neutrophilic leukemia (CNL), chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), and unclassified…”
Get full text

CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes by Edwards, David K, Rofelty, Angela, Agarwal, Anupriya, Kurtz, Stephen E, Traer, Elie, Lee, Patrice, Chantry, David, Loriaux, Marc, Druker, Brian J., McWeeney, Shannon K., Tyner, Jeffrey W.

“…Introduction: CSF1R (M-CSFR) is a receptor tyrosine kinase that, upon binding with CSF1 ligand (M-CSF), activates downstream survival, proliferation, and…”
Get full text

Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies by Kurtz, Stephen E, Eide, Christopher A., Kaempf, Andy, Khanna, Vishesh, Savage, Samantha L., Rofelty, Angela, English, Isabel, Ho, Hibery, Mori, Motomi, Traer, Elie, Druker, Brian J., Tyner, Jeffrey W.

“…Introduction: Translating the genetic and epigenetic heterogeneity underlying human cancers into therapeutic strategies represents an ongoing challenge…”
Get full text